Ranolazine Attenuates Trastuzumab-Induced Heart Dysfunction by Modulating ROS Production

Ranolazine Attenuates Trastuzumab-Induced Heart Dysfunction by Modulating ROS Production

The ErbB2 blocker trastuzumab improves survival in oncologic patients, but can cause cardiotoxicity. The late Na+ current inhibitor ranolazine has been shown to counter experimental HF, including doxorubicin cardiotoxicity (a condition characterized by derangements in redox balance), by lowering the...

Full description

Bibliographic Details
Main Authors: Gennaro Riccio, Salvatore Antonucci, Carmela Coppola, Chiara D'Avino, Giovanna Piscopo, Danilo Fiore, Carlo Maurea, Michele Russo, Domenica Rea, Claudio Arra, Gerolama Condorelli, Fabio Di Lisa, Carlo G. Tocchetti, Claudia De Lorenzo, Nicola Maurea
Format: Article
Language:English
Published: Frontiers Media S.A. 2018-02-01
Series:Frontiers in Physiology
Subjects:
trastuzumab cardiotoxicity
ranolazine
heart function
heart failure
oxidative stress
Online Access:http://journal.frontiersin.org/article/10.3389/fphys.2018.00038/full

Internet

http://journal.frontiersin.org/article/10.3389/fphys.2018.00038/full

Similar Items